OpenNashPodcasts

The Readout Loud (STAT)

249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

9 Mar 2023 · 38m · Robert Califf, Elaine Chen, Meg Terrell · 22 quoted facts

▶ Play episodeOriginal source ↗

In brief

The episode argues that two big shifts are under way in medicine. The FDA's commissioner, Robert Califf, says drug regulation must adopt digital evidence, treat advisory committees as discussions rather than votes, and confront misinformation. STAT's Elaine Chen argues that powerful new weight loss drugs are recasting obesity as a treatable disease, while raising hard questions about safety, stigma, drug-company influence and cost.

The central tension is promise versus affordability. Obesity drugs and a new cholesterol pill look strikingly effective, yet the proof of long-term benefit is still pending. Even at lower prices, insurers could cover only a small share of eligible patients before budgets strain. Califf's regulatory reforms and Lilly's failed Alzheimer's trial show how evidence, not enthusiasm, is meant to decide what gets used and paid for.

Key insights

  1. Lilly's Alzheimer's failure leaves amyloid thesis intact

    Solanezumab did not help symptom-free people with amyloid plaque, either on cognition or on plaque. Because it did not clear plaque without helping patients, which would have undermined Lilly's other amyloid-targeting drugs, Damian Garde called it a relief for the company.

  2. Merck's pill cut LDL cholesterol about 60%

    A mid-stage trial of an oral PCSK9 drug at the highest dose lowered LDL ('bad') cholesterol by about 60%. Existing PCSK9 drugs are injections that have not sold as widely as feared, so a pill might widen appeal.

  3. Califf wants advisory committees to advise, not vote

    He says a hurried vote at the end of a meeting gets treated as the decision, when the FDA alone decides. He wants the meetings to exchange expert thinking and make the agency's reasoning transparent.

  4. Insurers could not afford obesity drugs for all

    Chen said ICER's analysis found payers would face pressure once 0.1% of eligible people took Wegovy at current net prices. Even at a $7,500 yearly price, under 1% could take it without straining the system.

  5. Novo's funding reaches medical school obesity teaching

    Chen reported that Novo funds obesity coursework at medical schools, with one doctor tailoring curricula at 10 schools through a Novo grant. Novo says the activities are non-promotional, but experts called medical students a captive audience.

Questions

Why did Lilly's Alzheimer's drug solanezumab fail, and does it hurt Lilly's other Alzheimer's drugs?

In the A4 study of people with amyloid plaque but no symptoms, solanezumab did not improve cognition or plaque measures. Damian Garde said it does not damage Lilly's core amyloid hypothesis, because it did not show plaque removal without clinical benefit.

What is the new Merck cholesterol pill and why does it matter?

It is an oral drug targeting PCSK9 that lowered LDL cholesterol about 60% at the highest dose in a phase two trial. The existing PCSK9 drugs are injections, so a pill could be more appealing, and Merck is expected to start phase three in the second half of 2023.

What does the FDA do about misinformation?

Robert Califf said the FDA tries to anticipate public reaction when it announces decisions and puts out fuller information up front. It also watches social media and responds quickly, including calling reporters, when it thinks something is wrong.

Why is the FDA looking at changing advisory committees?

Califf says their purpose is to gather expert thinking, not to take a vote, since the FDA makes the decisions. He also said the agency will review conflict-of-interest rules, which are a particular problem for rare diseases where most experts work on treatments.

Can the healthcare system afford GLP-1 weight loss drugs for everyone who qualifies?

Probably not, according to Elaine Chen. Almost half of US adults are eligible for Wegovy, and ICER estimated that even at a fair price of about $7,500 a year, covering less than 1% would start to pressure the system.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Eli Lilly and Company spent roughly a decade or more and over $1 billion trying to prove solanezumab could treat Alzheimer's disease, according to Damian Garde.

“So this is a medicine that Eli Lilly spent about a decade, maybe more, and in excess of $1 billion trying to prove could be a viable treatment for Alzheimer's disease.”

0:02:27 · Host · Solanezumab

The A4 study, run out of Harvard, enrolled people with detectable brain amyloid plaque who had no Alzheimer's symptoms.

“It enrolled patients who were likely to develop Alzheimer's disease based on having amyloid plaque in their brain detectably, but had not experienced any symptoms whatsoever.”

0:03:02 · Host · A4 study

The A4 study of solanezumab showed no benefit on cognitive function or on amyloid plaques.

“The study did not work at all, either in terms of measures of cognitive function or in terms of the amyloid plaques in question.”

0:03:02 · Host · A4 results · 2023

Eli Lilly's stock price fell after the solanezumab A4 result was reported, which Damian Garde found curious.

“And yet, Lilly's stock price went down, which I, you know, it's probably a fool's errand to try to unpack why stocks move”

0:03:33 · Host · Lilly stock · 2023

Damian Garde said Lilly's donanemab, an amyloid-targeting drug in phase three, would have looked less likely to succeed only if solanezumab had cleared plaque without clinical benefit.

“the other molecules, like Lily's denanumab, the one that is now in phase three, which also target amyloid, that they would have less likelihood of success”

0:04:18 · Host · Donanemab · 2023

In a phase two study, the highest dose of Merck's oral PCSK9-targeting drug reduced LDL cholesterol by about 60%.

“basically, the highest dose reduced patients' LDL or bad cholesterol by about 60 % with a pill.”

0:04:44 · Host · Oral PCSK9 drug · 2023

Merck was expected to start a phase three trial of its oral PCSK9 drug in the second half of 2023, according to Meg Terrell.

“Merck is expected to start that in the second half of 2023”

0:06:11 · Meg Terrell · Phase three · 2023

Amgen's injectable PCSK9 drug has passed $1 billion in annual sales, while Regeneron's has not, according to Meg Terrell.

“I mean, the Amgen drug has surpassed $1 billion in annual sales. The Regeneron one hasn't.”

0:06:11 · Meg Terrell · PCSK9 sales · 2023

Robert Califf marked one year as commissioner of the U.S. Food and Drug Administration around March 2023.

“Dr. Robert Califf recently marked his one-year anniversary as commissioner of the U.S. Food and Drug Administration.”

0:06:53 · Host · FDA commissioner · 2023

Robert Califf said the current system filters out about 85% of ineffective candidates in phase one, two and early phase three trials.

“We winnow out 85 % of things that don't work in phase one, two, and early phase three trials.”

0:14:13 · Robert Califf · Drug trials

Robert Califf said the US spends about $3.4 trillion on health care yet has a life expectancy five years shorter than other high-income countries.

“we're spending $3.4 1 trillion on health care with outcomes showing a five-year shorter life expectancy than other high-income countries”

0:14:48 · Robert Califf · US health spending

Robert Califf said FDA advisory committees exist to gather expert thinking rather than to take a vote, since the FDA makes the decisions.

“Purpose of the advisory committee is not to take a vote. Purpose of the advisory committee is to get the thinking of experts about the problem at hand.”

0:15:55 · Robert Califf · Advisory committees

Robert Califf said most COVID-19 deaths since vaccines became available were preventable with free vaccination, with or without an antiviral.

“most of the people dying of COVID since the vaccines were unnecessary deaths that could have been prevented with a free treatment, either vaccination alone or vaccination plus an antiviral.”

0:20:23 · Robert Califf · COVID-19 deaths

Robert Califf said US infant formula in-stock rates had returned to pre-recall levels, though some rural areas still lagged.

“First of all, our in-stock rates are back to where they were before the recall.”

0:22:16 · Robert Califf · Formula shortage · 2023

Robert Califf said the WIC program accounts for over half of US infant formula, giving the companies in it a dominant market position.

“The WIC program is responsible for over 50 % of the formula.”

0:23:31 · Robert Califf · WIC and formula

The company formerly known as Weight Watchers acquired a telehealth company to give its members access to prescription weight loss drugs.

“This week, the company formerly known as Weight Watchers made headlines when it acquired a telehealth company that will enable its members to access prescription weight loss drugs.”

0:25:14 · Host · WW acquisition · 2023

The GLP-1 drugs discussed include Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro.

“They are Novo Nordisk's Ozempic and Wagovi and Eli Lilly's Monjaro.”

0:25:23 · Meg Terrell · GLP-1 drugs · 2023

Elaine Chen reported that one doctor, funded by a Novo Nordisk grant, is tailoring and integrating obesity curricula with 10 medical schools.

“there's one doctor who, you know, through a grant from Novo is working to actually tailor and integrate the curricula with 10 medical schools.”

0:29:16 · Elaine Chen · Medical school curricula · 2023

Elaine Chen said side effects of the new obesity drugs so far appear manageable, mainly early nausea and diarrhea, with some concern about rare pancreatitis.

“So far, the side effects seem relatively okay. There's nausea, diarrhea at the beginning. There's concern about maybe potentially rare cases of pancreatitis.”

0:32:38 · Elaine Chen · Drug safety · 2023

Elaine Chen said there is concern that older people on these drugs could lose lean muscle mass too quickly and become frail.

“there's some concern that they could lose lean mass too quickly, which could lead to them becoming more frail”

0:32:38 · Elaine Chen · Lean mass · 2023

Data show reduced cardiovascular events in diabetes patients taking these drugs, but not yet in people with obesity alone, according to Elaine Chen.

“for patients with diabetes taking them, there is a reduced risk of cardiovascular events. But we don't yet have data on cardiovascular events for people just with obesity.”

0:34:34 · Elaine Chen · Cardiovascular outcomes · 2023

Damian Garde estimated more than 100 million people in the United States might be candidates for obesity drug therapy.

“there's in excess of 100 million people, I think, just in the United States who might be candidates for therapy.”

0:35:12 · Host · Eligible population · 2023

Chapters

  1. 0:03:02Lilly's solanezumab fails in the A4 prevention study

    A long-running test of whether an amyloid-targeting drug could prevent Alzheimer's in symptom-free people came up empty. The hosts explain why that does not damage Lilly's broader strategy.

    “The study did not work at all”
  2. 0:04:44Merck's oral PCSK9 cholesterol pill

    A mid-stage trial suggests a pill can lower LDL about as much as injectable PCSK9 drugs. That could matter for a drug class that has not sold as widely as expected.

    “reduced patients' LDL or bad cholesterol by about 60 % with a pill”
  3. 0:08:32Califf on his first year and top priorities

    The FDA commissioner names misinformation and evidence generation as his biggest priorities. He frames year one as setting up and the next two years as implementing.

    “the two biggest ones are dealing with misinformation and the evidence generation system”
  4. 0:15:55Rethinking advisory committees and evidence

    Califf argues that digital health records should replace costly old-style trials. He also wants advisory committees to share expert thinking rather than end in a vote.

    “Purpose of the advisory committee is not to take a vote.”
  5. 0:22:16Baby formula shortage and Duke basketball

    Califf says formula stock has recovered but distribution is still patchy, with deeper industry problems outside FDA control. The interview ends on his Duke predictions.

    “our in-stock rates are back to where they were before the recall”
  6. 0:26:18Obesity as a disease, and its critics

    Elaine Chen explains how effective drugs are changing the idea that obesity is a willpower failure. She lays out worries about cost, environmental causes and weight stigma.

    “it's actually a disease that has a biological basis”
  7. 0:28:38Drug company influence in medical education

    Novo Nordisk's funding of obesity coursework at medical schools is unusual and troubles some experts. It shows how companies are shaping how obesity is taught.

    “pharma companies should not go anywhere near medical school curricula”
  8. 0:36:00Who can pay for the obesity drug boom

    Cardiovascular benefit data for people with obesity are still pending, while eligible patients number in the tens of millions. ICER's analysis shows how quickly costs would strain payers.

    “less than 1 % could take the drug”

Transcript

0:00:15
Meg Terrell

Welcome to this week's episode of The Readout Loud, a weekly biotech podcast from STAT. I'm Meg Terrell.

0:00:20
Host

I'm Adam Feuerstein. And I'm Damian Garde.

0:00:22
Meg Terrell

It's Thursday, March 9th, and here's what we're going to talk about this week.

0:00:25
Host

First, FDA Commissioner Dr. Robert Califf came to town and stopped by Stat. We asked him about his first year in the job, FDA's priorities, and the future of Duke basketball after Coach K. Then there are the biggest things to happen in the pharmaceutical industry since COVID-19. The new weight loss drugs are making waves, and Stat's Elaine Chen joins us to discuss them.

0:00:46
Meg Terrell

We start with a quick look at the week's other biggest biopharma news.

0:00:50
Host

But first, a word from our sponsor. Thank you.

0:01:25
Speaker 5

new era in medicine. Speakers include Stephen Gillett, the CEO of Verily, and Jennifer Doudna, the co-inventor of CRISPR. These experts will share their insights on how technology and innovation are transforming healthcare for the benefit of patients. Plus, the summit will be led by stat reporters, giving you access to the latest developments in the field and in-depth analysis of the industry. So join us this May 3rd and 4th at the Stat Breakthrough Summit, and be a part of the conversations delving into the incredible advancements happening in the field that are shaping the future of health care.

0:02:02

Learn more and register today for a limited discounted ticket at statnews.com slash summit.

0:02:13
Meg Terrell

We've been a little bit spoiled recently with positive news in the Alzheimer's space, But on Wednesday evening, we got a negative study on a Lilly Alzheimer's drug. Damian, tell us about solonizumab.

0:02:27
Host

Yeah, remember, I'm dusting off a big book on my desk marked solonizumab. So this is a medicine that Eli Lilly spent about a decade, maybe more, and in excess of $1 billion trying to prove could be a viable treatment for Alzheimer's disease. The company has since, if not moved on, but progressed other molecules that we've talked about on this podcast that seem to have a higher likelihood of success. However, solonazumab being probably the state of the art circa 2012-13 was the star of this study called the A4 study run out of Harvard, which was pretty ambitious.

0:03:02

It enrolled patients who were likely to develop Alzheimer's disease based on having amyloid plaque in their brain detectably, but had not experienced any symptoms whatsoever. So completely asymptomatic patients. And the idea was if you gave them solanazumab over a long period of time, they would be less likely to actually develop the disease. Cutting to the lead, which I should have started with, Meg, as you mentioned, that did not work. The study did not work at all, either in terms of measures of cognitive function or in terms of the amyloid plaques in question.

0:03:33

And curiously, I saw this news on Wednesday night and thought, Well, sure, because most of the neurological world, neuroscientific world has moved on from solanazumab. There are better mousetraps available that do ostensibly the same thing. And yet, Lilly's stock price went down, which I, you know, it's probably a fool's errand to try to unpack why stocks move, especially big pharma stocks that are so widely traded and widely held and expensive as Lilly's is. But I thought it was curious because really, if there were bad news baked into this for Lily, it would be if solanazumab did have a marked effect on amyloid plaques in people's brains, but still had no benefit on the actual clinical outcomes of treatment.

0:04:18

But that didn't happen. And the reason that would be bad is because it would suggest that the other molecules, like Lily's denanumab, the one that is now in phase three, which also target amyloid, that they would have less likelihood of success because apparently removing amyloid did not actually have a benefit in this population. But because that didn't happen, the core hypothesis of Lily's whole approach to Alzheimer's disease remains intact. And you can disagree with it if you want, but this study doesn't really affect the conversation.

0:04:44

So, big sigh of relief for Lily. So Damian, you were just at the American College of Cardiology meeting in New Orleans. What was the most important data you saw there? Well, I don't know what was most important, but what was definitely most intriguing to me was a phase two, a mid-stage study run by Merck of an oral treatment that targets cholesterol. And, you know, cutting through, there's multiple cohorts in the study in different doses, but basically, the highest dose reduced patients' LDL or bad cholesterol by about 60 % with a pill.

0:05:17

And this is a pill that targets PCSK9, which we've discussed on this podcast at some length. And the fact that it exists is a sort of chemical engineering, not miracle, but it's a coup of some

0:05:30
Meg Terrell

sort. And its efficacy seems like it could be important going forward. Yeah, we had, you know, how they were developing this molecule and why. And of course, this class of drugs targeting PCSK9 are now injectables. And they have shown similar levels of cholesterol lowering. But there is an argument that if you could just take a pill the same way you can take a statin right now, that might be way more appealing to people. You have not seen this class of drugs really take off in the way that Wall Street hoped and that the insurance and PBM space seem to fear.

0:06:11

There were warnings at the time that this would break the healthcare system. And really, that hasn't happened. I mean, the Amgen drug has surpassed $1 billion in annual sales. The Regeneron one hasn't. And so, you know, we'll see how this does in phase three. Merck is expected to start that in the second half of 2023. But could this make, you know, this class of drugs and the power it has with lowering LDL cholesterol just more palatable for people, that will be really interesting to watch.

0:06:53
Host

Dr. Robert Califf recently marked his one-year anniversary as commissioner of the U.S. Food and Drug Administration. He happened to be in Boston this week, so we snagged him for a few minutes of podcasting. Commissioner, welcome to the Readout Loud. Thanks. Good to be here. So, as we said, you just passed through your one-year anniversary as FDA commissioner. I wonder, does serving one year as FDA commissioner, does that feel like one year or does it feel like 10 years?

0:07:18
Robert Califf

Well, this time around, it's so much more complex than it was in 2016. It feels a bit longer, but the challenges are great and the mission is great.

0:07:26
Host

Well, so to that point on the challenges, I know you came in with a list of priorities for the second go round. How is it going? What do you think has gone right and what has proved to be more evasive or more elusive than you might have thought?

0:07:40
Robert Califf

Well, as I said, I think things are much more complicated this time around. The politics are more difficult. There's greater division in the country and the pervasive effect of misinformation is everywhere. But I also just looked at we have over 20 priorities. This is separate from all the priorities each center has with its own products. These are overarching issues across the FDA. And I'm very happy with the progress made on really all of them. So I feel pretty good about what we've accomplished.

0:08:13

The proof will be in the pudding over the next two years because the first year is getting things in line. The next two years will be about implementing what we are working on.

0:08:23
Meg Terrell

Maybe go through a few of the priorities that you're really focused on, either that you've already started work on and that will continue, or that you're really focused on for the year ahead.

0:08:32
Robert Califf

Sure. I mean, the two biggest ones are dealing with misinformation and the evidence generation system in this country. On misinformation, we have a very different and proactive approach at the FDA trying to pre-bot, re-bot, move quickly, respond to information we think is incorrect. But it's also true that the Internet is rife with more and more people that are spewing out information, which is detrimental to people. And, you know, the proof of it in the U.S.

0:09:06

is our decline in life expectancy. So I feel like we've made great progress on misinformation, But the misinformation ecosystem is moving faster than we are. So we'll keep working on that.

0:09:19
Meg Terrell

Sorry, just to interrupt really quick. What does the FDA do itself about misinformation? What's the FDA's role there?

0:09:25
Robert Califf

Well, it starts with when we reach a decision based on high-quality evidence, thinking ahead about how people might react to it so that we put out more comprehensive information that would cover the issues that people are likely to react to. And then the minute we put something out now, a huge number of people are reactive to it on social media. And by following that and tracking social media, we're reacting more quickly when we think someone has gotten off course or, you know, this would never happen at stat, of course, but if a news story was incorrect, then we're on the phone quickly to provide the additional information.

0:10:09

And so there's much more to it than that. And I hope that the world of universities and health systems and other folks will pick up their game, too, because that's what it's really going to take to move things in the right direction.

0:10:25
Host

So the year's biggest cardiovascular conference just wrapped up in New Orleans. I know you're not allowed to comment on individual drugs in development, but, you know, considering you're a heart doctor by training, I wonder what you make of the pipeline of new cardiovascular medicines. You know, heart disease remains the number one killer, yet we don't see as many novel therapies as we do in cancer or rare diseases. Why is that?

0:10:48
Robert Califf

Well, I used to be really, really exercised about this even recently, but there has been a number of new drugs recently that are disease-modifying drugs in the area of heart failure. I noticed at the ACC there's a new lipid-lowering drug with a different mechanism that, at least according to the clinical trial, has a significant benefit. The obesity, diabetes drugs, really life-saving drugs developed in the last few years. So I think we are on a roll now, I think, in cardiovascular drugs.

0:11:24

Well, we've got to figure out how to get them distributed to the right people in a more effective way. And again, I particularly point to the obesity drugs as an area where these are entirely unexplored pathways in terms of pharmacologic intervention. They're going to tell us a lot about the biology of obesity, diabetes, and cardiovascular events related to that. So I think it's really an exciting time. And, you know, I didn't even mention devices, but who would have thought we'd be replacing valves percutaneously?

0:11:58

and now into this next second and third generation of technologies there.

0:12:03
Host

So on that topic, it feels like we're entering kind of a new age of medicine, thanks to those powerful weight loss treatments that you mentioned, two of which, or well, one of which recently won FDA approval for obesity, another to come, and many more in the pipeline. I think a major reason for that change is the agency's decision to deem obesity as a medical indication. There was time in which, you know, that was kind of controversial as to whether you could win FDA approval for a drug with that indication.

0:12:30

That hasn't been without controversy. And so I'm curious, what do you think of the argument that, you know, simply having a BMI, a high BMI, is not in itself a disease to be treated and the sort of social cultural angle of, you know, people's bodies and what is a medicalized condition and what is not?

0:12:47
Robert Califf

That is such a complicated question to answer in a short podcast. I'll just say in the long run, I am very sure that the drugs that are going to be most used are going to be the ones that not only lower body weight, but also lead to better composite clinical outcomes, not just cardiovascular events, but less joint difficulty. We can go on and on with the medical complications that occur during a long course of overweight. And so while in the short term, losing weight, you know, is the arguments will continue.

0:13:27

In the long run, we got to get our sites focused on living longer and being more functional, which is really what this should be all about.

0:13:37
Meg Terrell

Yeah, and I think there'll be some fascinating trials coming up this year, which will seek to answer some of those questions on Novo's drug, for example, which is approved for obesity. I interrupted you earlier as you were outlining the second of your priorities, which was an improving evidence generation. And I wonder along those lines, you know, we also have a question we wanted to ask you about your focus on potentially a need to overhaul advisory committee meetings.

0:14:00

So maybe kind of combine those answers as you're thinking about better evidence generation, Then also how we bring in experts to help the FDA think about approving drugs. How do you want to change that system?

0:14:13
Robert Califf

Well, so first of all, you know, I think our evidence generation system for early drug and device development is fit for purpose and does the job. We winnow out 85 % of things that don't work in phase one, two, and early phase three trials. Beyond that, we're falling so far short of what our technology can offer now. Why should anyone have to recreate demographics, problem lists, medication lists, major clinical events? They're all captured in digital form now in our health systems.

0:14:48

And so particularly as we're entering this era where CMS is also aware we're spending $3.4 1 trillion on health care with outcomes showing a five-year shorter life expectancy than other high-income countries. We've got to fill in those evidence gaps, and we can't do it by doing old-fashioned, labor-intensive clinical trials. we need to move into the digital world. Realizing, of course, that randomization is still really important to get a lot of the answers that we need.

0:15:24

But the ornaments that we've hung on those randomization trees of all this extra data and the way we do it, just far too expensive. Now, of course, generating the data is one thing. Then we've got to consume it, and advisory committees should be very helpful there. The public should expect that the FDA is interacting with the outside world and interacting with experts of various types, whether it's patients reflecting their experience or experts in the disease or the interventions.

0:15:55

And, you know, we're working on that. And I'd say the main thing that I want to get across is we need those interactions. Purpose of the advisory committee is not to take a vote. Purpose of the advisory committee is to get the thinking of experts about the problem at hand. the FDA is charged with making the decisions. The advisory committee is advisory. And I think people have gotten far too focused on voting and not focused enough on exchanging knowledge and information that can assist the FDA in making its decision and also provide transparency to the public about what the thinking is behind those decisions.

0:16:33
Host

So two-part follow-up there. One, when it comes to advisory committee meetings, obviously there's oftentimes a vote. There's a voting question where the panelists will be asked to vote on essentially the approvability question. So do you think that, would you like to see less of those kinds of sort of penultimate voting questions at ad comps? And then second, one of the other issues I think with ad comps is the people who are invited, the experts who are invited.

0:16:59

We often see people who are experts in the field who, for conflict of interest reasons, cannot participate in advisory committees. Would you like to see some changes to conflict of interest so that you could have more relevant experts weigh in on these decisions?

0:17:16
Robert Califf

So first of all, I would like to see fewer meetings ending up with a hurried vote at the end and everybody rushing out of the room and then somebody claiming that, you know, that's like the decision. It was interesting that you use the word penultimate. I would just prefer or it not even be referred to as any version of ultimate. But what's really important is the thinking that goes on and making sure that the committee has a chance to review and interact to bring out the thinking.

0:17:47

And in terms of conflict of interest, we're going to take a step back and look at all of that. It's particularly an issue with rare diseases, as you know, where, I mean, show me an expert in a rare disease who's not working on a therapeutic intervention.

0:18:01
Host

You know, it's funny you say that because I think oftentimes when I watch the rare disease advisory committees and you know, you look at the panel and not to denigrate anybody who's invited to the panel. Obviously, they're, you know, they're doing a public service by appearing in these ad accounts. But you know that there are experts because they've participated in clinical trials or in the development or consulted. They can't participate in this.

0:18:23
Robert Califf

Yeah, so what I want to do is have a discussion that's independent of any particular disease or problem about what the principles are. So we can then go back and apply the principles, which may be different for drugs or devices, for example, that are for very broad application to a general population. There are going to be a lot of experts who are unconflicted. And for some other diseases, it may be quite different. That's only part of it.

0:18:48

We're going to look at the whole stem discern. We had an executive committee meeting at FDA of the leadership. Everyone wanted to work on the advisory committee system and make it better.

0:18:57
Host

So, Commissioner, you probably won't remember this, but in, I think, 2018, I ran into you on a street corner in Austin, Texas. And I introduced myself and told you where I worked. And you were very polite, but your parting words were, I think, for stat, you know what you guys should be covering is this whole right to try thing. And people may recall that was at the time pending legislation that I don't want to put words in your mouth, but a lot of people perceived as an effort to basically reduce the authority of the FDA.

0:19:26

And a lot of people took that further into, you know, therefore potentially imperil public health. So my question is not about right to try, but rather today where that interaction happened, what would you tell me or some reporter? This is what you should be covering. This is the challenge or the risk to the FDA or to public health in general that is not getting enough attention.

0:19:46
Robert Califf

You just cannot give too much attention to the misinformation problem. And it's just gotten to be a huge issue because of the way social media and the Internet have developed. I don't think people are fundamentally any different. We had snake oil salesmen back in the days when you advertised in magazines to get your word out if you're a snake oil salesman. And we have a lot of legitimate argument and debate. And it's so hard for the average person to sort out when it's legitimate argument and debate and when someone is posing as an expert when they're really not.

0:20:23

So there's a lot to cover there. I hope you guys spend a lot of time on it and help sort it out, because if you just look at COVID as an example, most of the people dying of COVID since the vaccines were unnecessary deaths that could have been prevented with a free treatment, either vaccination alone or vaccination plus an antiviral.

0:20:47
Host

So there's a lot of animosity towards public health officials these days. It's part of this, you know, kind of part of some misinformation. Are you seeing that as you try to attract people to come to work at the FDA or retain people at the FDA, people that you need to complete the mission of the agency? Is that are you running up against it? Is that is that an issue for you?

0:21:09
Robert Califf

So first of all, I'll just say that we do better in hiring than most people think. We actually do pretty well in hiring. But there is a trend that I've noticed, as I call people, particularly for high-level jobs, that they're very concerned about the public, not just the public scrutiny, it's really the attacks, the physical threats, the threats to family. This has gotten out of hand, and people are very aware of it. I like to think that appealing to patriotism and to public health is a good antidote to that.

0:21:44

For the most part, it has been. But it's an aspect of the sort of general issues and misinformation, which is completely out of hand right now.

0:21:55
Host

I want to ask about the baby formula shortage. I think that's kind of escaped the headlines in recent months. But I do think there is still difficulty for people out there trying to find formula even recently. What's the status of that shortage? And how can the FDA help ensure that it doesn't happen again? and that manufacturing is safe so that babies are safe?

0:22:16
Robert Califf

First of all, our in-stock rates are back to where they were before the recall. And I think there are some areas, particularly in rural America, where the distribution has still not gotten back to where it needs to be. And the manufacturers have consolidated the variety that they make in order to focus on producing the maximum amount possible. So while things are a lot better, it's far from perfect and some people are still having trouble. Voluntarily, the companies are giving us their production data and their distribution data so that we can plan and intervene when problems occur, something that we couldn't do before because we didn't have that data.

0:22:59

And there's always a balance. We have to make sure the formula is safe and that it's nutritious, but we need to keep the supply up. And so there's a lot of work that a whole team of people do and working with the manufacturers to stay on top of that. But there are larger issues that are well beyond the FDA. This is a consolidated industry that depends largely on a few plants that are older. And we'll need to really work on the industrial policy here.

0:23:31

The WIC program is responsible for over 50 % of the formula. and the companies that are in the WIC program have a dominant position in the market, making it harder for others to come in. And that's not an easy one to solve. This is not an issue for FDA to decide. So, you know, I learned early in my career to never say, we'll never happen again, but we're doing a lot that will make it very, very unlikely this is going to happen again.

0:24:02
Host

So let's end on a sports note. Commissioner, you are a huge fan of Duke basketball. We're recording this interview on Monday, so it's just ahead of the ACC tournament. How are you feeling about Duke's March Madness odds this year, particularly in this sort of post-Coach K era?

0:24:21
Robert Califf

Yeah, you know, there was a great interview. I've always loved listening to Chris Wallace, and he interviewed Coach K last night. It's worth listening to if people get a chance. And, you know, our kids grew up with Coach K's kids, so it's been fun for me to follow the teams. I feel great right now. You know, it's a super talented team. They had a lot of injuries early in the year. John Shire's a new coach. They're in their stride right now, and they've been on a win streak.

0:24:47
Host

For the big tournament, where do you think Duke ends up?

0:24:49
Robert Califf

I think Duke will probably get into the Elite Eight, but it's going to be hard. It's really just a play of chance, I think, as to who gets in that Final Four.

0:24:58
Host

Well, Commissioner Caleb, thanks so much for joining us today.

0:25:01
Robert Califf

You bet. Good to be with you.

0:25:14
Host

This week, the company formerly known as Weight Watchers made headlines when it acquired a telehealth company that will enable its members to access prescription weight loss drugs.

0:25:23
Meg Terrell

And we've talked about this class before. GLP-1s are so-called incretin mimetics. And yes, we are still trying to make incretin happen. They are Novo Nordisk's Ozempic and Wagovi and Eli Lilly's Monjaro.

0:25:35
Host

These drugs are becoming a bigger and bigger story, both culturally and on Wall Street. And STAT has started a series called The Obesity Revolution to explore their impact. The first installment came out this week, and reporter Elaine Chen joins us now to discuss. Elaine, welcome back to the Readout Loud.

0:25:52
Elaine Chen

Thanks so much for having me on again.

0:25:54
Host

So maybe like the 10 ,000 foot view and sort of the framing of your story is that obesity long perceived or long described as the result of poor lifestyle choices is now being much more widely considered to be a disease that can be treated and ought to be treated. So how has the arrival of these new and very powerful medicines changed that old narrative?

0:26:18
Elaine Chen

Yeah. So a lot of people feel that because these new class of medications are so effective at helping people lose weight, that's helping change the narrative that obesity is not a result of a failing of willpower, but it's actually a disease that has a biological basis. Because if you can treat something effectively with a medication that just shows that the underlying problem itself was a biological problem in the first place.

0:26:47
Meg Terrell

And of course, that's a message that's really being embraced by Eli Lilly and Novo Nordisk and maybe even more than embraced, but forwarded and pushed along by these companies. That, you know, this is a biological disease that can now be treated with a medicine. These early ones are mostly injectables and they need to be taken chronically. And of course, you know, we've seen the stories that weight rebounds if these drugs are stopped. So what do critics say is wrong with this message and its framing?

0:27:17
Elaine Chen

There are several concerns about not so much kind of this message itself. I think a lot of doctors in the medical community believe that, you know, obesity is biologically based. But the concern is taking the message too far. So one aspect is we have a big financial constraints in terms of, you know, how the system can pay for all these drugs for everybody who is currently eligible for them. Because we just feasibly probably can't treat everybody who is eligible for these drugs.

0:27:44

there needs to be a better way of figuring out who's most likely to experience complications from obesity, who might need these drugs the most. There's also concern that as these drugs become more widespread, the medical community might start to ignore the environmental causes of surging obesity rates, like lack of access to healthy food or physical activity. And then lastly, there's also concern that this message could further contribute to weight stigma by telling people, you know, this is a disease, there's something wrong with you, and it might even be harmful for people at risk of eating disorders.

0:28:23
Host

So sticking with this topic of the way sort of pharma is framing these obesity treatments, in your story, you report that Novo is funding coursework on obesity for medical schools. What did Novo tell you about this effort and what's been the response from critics?

0:28:38
Elaine Chen

It's more rare for pharmaceutical companies to get involved at this level. It's really common for them to fund continuing medical education for already licensed doctors, but to get at the level of medical schools is very rare. Novo said that all of their educational activities are non-promotional and developed by third parties. But still, some experts we asked about this were really startled and said that pharma companies should not go anywhere near medical school curricula, especially medical students are a really captive audience and don't have the experience that licensed doctors do.

0:29:16

And, you know, in addition to that, there's one doctor who, you know, through a grant from Novo is working to actually tailor and integrate the curricula with 10 medical schools. So, you know, getting pretty deep and working directly with some medical schools.

0:29:33
Host

So I want to go back to the Weight Watchers, formerly WW news that we mentioned, because it seemed like that single headline kind of encapsulated a lot of the concerns that you wrote about in your story and that have been articulated by people around the world as these drugs have risen, which is that there had seemed to be a gradual cultural and somewhat medical pivot away from a focus on weight specifically. And Weight Watchers, a famous brand of the 1990s, dropping the word weight from its name, seem to be illustrative of that.

0:30:06

And we've seen this in marketing and in just the way we talk about people's bodies has shifted over the past decade. And then these drugs arrive, and they are very, very powerful at reducing people's weight. And suddenly, it seems like the culture is gradually reconfiguring itself back to that old model. and then, you know, Weight Watchers as sort of a canary in the coal mine, perhaps, for that change, is not only calling itself that again, but buying a company such that it can get in on the business of helping people access these medicines.

0:30:36

There's a really long-winded way of saying, you know, what are the implications of, for example, you know, telehealth access to these drugs, about people being able to potentially get on them without going through the normal means of having it prescribed by a physician who actually knows them and has seen them in person?

0:30:54
Elaine Chen

Yeah, the Weight Washers news is really interesting. It seems like there's been an explosion of telehealth companies trying to get in on this, you know, potentially goldmine of the GLP-1 medications. I think that, you know, on one hand, people could say that it makes it a lot easier for people to get access to these medications to be able to just get them through telehealth. But as various reporters have reported, there are some issues with offering these through telehealth, such as, you know, how well can you verify kind of who your customer is?

0:31:29

And also, how do you kind of offer something that helps them beyond, you know, just them regularly going to the doctor? A lot of these telehealth programs say they offer lifestyle intervention and counseling, but how well can you really do that through telehealth? And then they also say they can help you better navigate insurance difficulties. But again, how much better is that than just going to a regular doctor? So I think a lot of these telehealth programs still are trying to figure out what value they add.

0:31:59
Meg Terrell

And to that point, you know, about the sort of explosion of these medicines and their potential ubiquity, you know, Wall Street analysts are saying this could be the biggest class of drugs maybe ever. So with so many people taking them and perhaps some for long periods, I've seen comparisons to statins. You know, you have to stay on them to keep your cholesterol low. With these, maybe you have to stay on them to keep your weight off.

0:32:22

So how much is understood about the safety of these drugs, particularly over the long term? because you and Matt Herper, your co-writer on the story, did this great look at the history of obesity drugs and the fact that it's been plagued with safety issues, right?

0:32:38
Elaine Chen

Yeah, I think a lot of people, because of the fraught history of weight loss medications, are kind of on the lookout to see if we're going to see any big safety concerns with these class of medications. So far, the side effects seem relatively okay. There's nausea, diarrhea at the beginning. There's concern about maybe potentially rare cases of pancreatitis. But then, you know, we still need more data to see what the long-term effects are. And then, you know, something else that I've recently heard about is, especially for older people taking the medications, there's some concern that they could lose lean mass too quickly, which could lead to them becoming more frail.

0:33:18

And so that's kind of a concern because these drugs, when they help people lose weight. It's both fat mass and lean mass. Interestingly, they point that out. I'm

0:33:27
Meg Terrell

sorry if somebody else was about to say something, but like, that's one of the things that I noted with the Weight Watchers story is that they emphasize, at least in the Wall Street Journal article, you know, which is the first, you know, they sort of got the story on it. They pointed out the combination with the counseling that they provide would point people toward sort of high protein diets and weight training that could help them maintain their muscle mass, maybe to counterbalance some of those effects of the rapid weight loss you see with these drugs.

0:33:59

So that's a

0:34:00
Host

really interesting point. So Meg mentioned the statins and the statins became huge drugs, not only because they lower cholesterol, because there were studies that showed that lowering cholesterol led to better outcomes for patients, fewer heart attacks, prolonged survival, you know, real things that really matter to people in the long term. What kind of data do we have on that with these weight loss drugs? And if we don't, when will we know whether, you know, weight loss unto itself will lead to better outcomes for people?

0:34:34
Elaine Chen

Yeah. So these medications, which were originally developed for diabetes, we do have data that show that for patients with diabetes taking them, there is a reduced risk of cardiovascular events. But we don't yet have data on cardiovascular events for people just with obesity. There is a big trial from Novo Nordis that's expected to, we're supposed to expect to hear results later this year. So we'll see. That could be a really pivotal trial. Eli Lilly is also having one underway, but that one's going to take a bit longer time.

0:35:12
Host

So those data on long-term outcomes for this class of medicines of people with obesity are important, obviously, scientifically for us to understand how well they work, but are also massively important to both the business and economic angles of this in that, you know, multiple people have said, and you have in your story, that for these drugs to get widespread insurance coverage, they will have to succeed in improving long-term outcomes. And then the other side of that is if they do, you know, there's in excess of 100 million people, I think, just in the United States who might be candidates for therapy.

0:35:46

How are we going to pay for all of that? So I don't know how to like frame that as a question to you. But like, you know, what should we be thinking about in terms of the monetary angle of this as this story moves forward? Yeah, the financial

0:36:00
Elaine Chen

constraints is going to be a big issue. Currently, say for Wigofi, almost half of the US population is eligible for it. And ICER did some analysis that showed that at the current net price, as soon as 0.1 % of the eligible population takes the drug, payers would have to either shift money around or increase premiums. So it would have an effect. And even if the cost comes down to what ICER deems a fair cost-effective price of around $7 ,500 a year, still they estimate that less than 1 % could take the drug without the health system starting to get pressured.

0:36:40

So I don't know. I don't have an answer to how to deal with that. But just going back to what I said earlier, I think that's why doctors think we need to think hard about who needs the drugs the most and in focus efforts there.

0:36:53
Host

You can imagine that there's like actuaries inside insurance companies right now who are basically freaking out over this entire market.

0:37:03
Meg Terrell

Elaine, thanks so much for joining us. Thank you so much.

0:37:15
Host

That does it for another episode of The Readout Loud. Thank you to Teresa Gaffney for producing this week's episode.

0:37:20
Meg Terrell

Our senior producers are Hyacinth Embanado and Alyssa Ambrose. Our executive producer is Rick Burke. And our theme music is by Brian Joel.

0:37:27
Host

We'd love to hear from you. Tell us what you like about this week's episode, what you didn't like, and whether you prefer Rob Kaler's professorial bow ties or Scott Gottlieb's funky socks. You can do all that by sending us an email at readoutloud at statnews.com. And if you like what we do, leave a review or rating on Apple Podcasts or whichever platform you use to get your podcasts.

0:37:47
Meg Terrell

See you next week.